<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04776629</url>
  </required_header>
  <id_info>
    <org_study_id>Ort-2020-01</org_study_id>
    <nct_id>NCT04776629</nct_id>
  </id_info>
  <brief_title>A Proof-of-Activity Study With Orticumab in Subjects With Psoriasis and Cardiometabolic Risk Factors</brief_title>
  <official_title>A Multi-Center, Randomized, Double-Blind, Placebo-controlled Proof-of-Activity Study With Orticumab in Subjects With Moderate-to-Severe Psoriasis and Cardiometabolic Risk Factors</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Abcentra</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Abcentra</source>
  <oversight_info>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The primary purpose of this proof-of-activity, phase 2 trial is to evaluate the safety and&#xD;
      activity of orticumab in subjects with moderate to severe psoriasis and cardiometabolic risk&#xD;
      factors.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This randomized, double-blind, study is designed to compare the effect of orticumab against&#xD;
      placebo in subjects with moderate to severe psoriasis and cardiometabolic risk factors. A&#xD;
      total of 75 subjects will be randomized in a double-blind fashion to receive intravenous (IV)&#xD;
      infusions either of orticumab or placebo for up to 78 days.&#xD;
&#xD;
      Participants will be enrolled into one of the two groups: active treatment or placebo.&#xD;
      Subjects will be randomized in a 2:1 ratio, orticumab to placebo and receive up to 11 weeks&#xD;
      of treatment.&#xD;
&#xD;
      Planned treatments are weekly x 4 , then monthly x 2 . The Internal Safety Review Committee&#xD;
      (ISRC) will review the blinded safety data after the first subject completes the first dose&#xD;
      (Day 1), the first five subjects complete the first dose (Day 1), and the first ten subjects&#xD;
      complete the first dose (Day 1). The IRSC will review all adverse reactions to all&#xD;
      administered doses at these times.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">June 30, 2021</start_date>
  <completion_date type="Anticipated">December 2022</completion_date>
  <primary_completion_date type="Anticipated">September 2022</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Mean percent change from Baseline in Psoriasis Area Severity Index (PASI)</measure>
    <time_frame>106 days (Week 15)</time_frame>
    <description>PASI combines the assessment of the severity of lesions and the area affected into a single score in the range 0 (no disease) to 72 (maximal disease)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Percentage of participants achieving treatment success by the 5-point static Investigator's Global Assessment modified 2011 version (sIGA) Score</measure>
    <time_frame>106 days (Week 15)</time_frame>
    <description>Percentage of participants achieving treatment success (clear =0 or almost clear =1) and greater than or equal to (&gt;=) 2 Point Improvement at Week 15 on the sIGA scale</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Incidence of Treatment Emergent Adverse Events (TEAEs)</measure>
    <time_frame>106 days (Week 15)</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Incidence of serious adverse events (SAEs)</measure>
    <time_frame>106 days (Week 15)</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Incidence of abnormal hemodynamic parameters</measure>
    <time_frame>Weeks 3, 7, 11 and 15</time_frame>
    <description>heart rate (HR) and blood pressure (BP)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Incidence of abnormal laboratory tests results</measure>
    <time_frame>Weeks 3 and 15</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Incidence of abnormal physical examination findings</measure>
    <time_frame>Weeks 3, 7, 11, 15</time_frame>
    <description>Physical examination will include the following organ or body system assessments: general appearance; eyes; ears, nose, and throat; head and neck; chest and lungs; cardiovascular; abdomen; musculoskeletal; lymphatic; dermatological; neurological; and extremities.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Mean percent change from Baseline in Psoriasis Area Severity Index (PASI)</measure>
    <time_frame>Weeks 1, 3, 7, and 11</time_frame>
    <description>PASI combines the assessment of the severity of lesions and the area affected into a single score in the range 0 (no disease) to 72 (maximal disease)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants achieving PASI75 and PASI50</measure>
    <time_frame>Weeks 1, 3, 7, and 11</time_frame>
    <description>PASI75 is a 75 percent reduction in PASI score. PASI50 is a 50 percent reduction in PASI score</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean percent change in Baseline in Body Surface Area (BSA) % involvement</measure>
    <time_frame>Weeks 1, 3, 7, 11, 15</time_frame>
    <description>Minimum: 0 percent, Maximum: 100 percent. Higher percentage indicates more skin with psoriasis.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean change from Baseline in Dermatology Life Quality Index (DLQI) score</measure>
    <time_frame>Weeks 3, 7, 11, 15</time_frame>
    <description>DLQI is a ten-question questionnaire used to measure the impact of skin disease on the quality of life of an affected person. Each question is scored from 0 to 3, giving a possible score range from 0 (meaning no impact of skin disease on quality of life) to 30 (meaning maximum impact on quality of life).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean change from Baseline in Itch Numerical Rating Scale (INRS) Score</measure>
    <time_frame>Weeks 3 and 15</time_frame>
    <description>The Itch NRS is a self-administered subject reported outcome questionnaire that is completed during protocol specified clinic visits. Participants indicate itch severity by circling the integer that best describes the worst level of itching due to psoriasis in the past 24 h on an 11-point scale anchored at 0, representing 'no itching' and 10, representing 'worst itch imaginable'.</description>
  </secondary_outcome>
  <other_outcome>
    <measure>Change in Coronary Artery Inflammation by CCTA</measure>
    <time_frame>106 days (Week 15)</time_frame>
    <description>Change in coronary artery perivascular fat attenuation index (FAI) measured by coronary computed tomographic angiography (CCTA)</description>
  </other_outcome>
  <other_outcome>
    <measure>Change in coronary artery plaque burden by CCTA</measure>
    <time_frame>106 days (Week 15)</time_frame>
    <description>Change in total, noncalcified and low attenuation coronary artery plaque volume</description>
  </other_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">75</enrollment>
  <condition>Psoriasis</condition>
  <condition>Inflammation</condition>
  <condition>Coronary Artery Disease</condition>
  <condition>Cardiometabolic Syndrome</condition>
  <arm_group>
    <arm_group_label>Active Treatment</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Dosage: Repeating intravenous dose. Administered by infusion over 30 minutes.&#xD;
Frequency and duration: once weekly x 4 weeks, then once monthly x 2 months.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Dosage: Repeating intravenous dose. Administered by infusion over 30 minutes.&#xD;
Frequency and duration: once weekly x 4 weeks, then once monthly x 2 months.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Orticumab</intervention_name>
    <description>A human recombinant monoclonal antibody against a specific oxidized low-density lipoprotein (oxLDL) epitope</description>
    <arm_group_label>Active Treatment</arm_group_label>
    <other_name>MLDL1278a; BI-204; Anti-oxLDL Antibody</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Placebo for orticumab, containing all components of formulation except the active ingredient</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion criteria:&#xD;
&#xD;
          -  Stable/chronic plaque psoriasis with PASI score of ≥ 12 AND involving ≥ 10% of the&#xD;
             subject's BSA.- ≥ 30 years of age at time of consent.&#xD;
&#xD;
          -  BMI ≥ 30 kg/m2&#xD;
&#xD;
          -  LDL ≥ 100 mg/dL at Screening.&#xD;
&#xD;
          -  All females must have a negative serum pregnancy test result at Screening and a&#xD;
             negative urine pregnancy test prior to dosing.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
        Subjects are excluded from the study if any of the following criteria are met:&#xD;
&#xD;
          -  Past use of orticumab.&#xD;
&#xD;
          -  Any of the nonplaque forms of psoriasis: erythrodermic, guttate, or pustular.&#xD;
&#xD;
          -  Scalp, palmar or plantar psoriasis only, at Screening or Baseline.&#xD;
&#xD;
          -  Have evidence of skin conditions (e.g., eczema) at the time of Screening or Baseline&#xD;
             visit that would interfere with theevaluation of psoriasis.&#xD;
&#xD;
          -  Newly discovered Type 2 diabetes mellitus (T2DM)&#xD;
&#xD;
          -  Moderate or high-intensity statin use or new use of a low-intensity statin therapy.&#xD;
&#xD;
          -  No use of anti-coagulating or anti-thrombotic agents.&#xD;
&#xD;
          -  Poorly controlled hypertension&#xD;
&#xD;
          -  Use of an IL-23 blocker in the past 180 days, an IL-17 blocker in the past 16 weeks,&#xD;
             or a TNF blocker in the past 12 weeks.&#xD;
&#xD;
          -  Use of methotrexate, cyclosporine, or apremilast in the past 4 weeks.&#xD;
&#xD;
          -  History of hypersensitivity or allergies to any contents in the orticumab formulation.&#xD;
&#xD;
          -  A history of any clinically important abnormalities in cardiac rhythm or conduction.&#xD;
&#xD;
          -  A history of prolonged QT intervals or a family history of long QT-syndrome at&#xD;
             Screening.&#xD;
&#xD;
          -  A history of first, second or third-degree atrioventricular (AV) block, or AV&#xD;
             dissociation.&#xD;
&#xD;
          -  A history of complete bundle branch block.&#xD;
&#xD;
          -  Unstable angina pectoris, myocardial infarction, transient ischemic attack, or stroke&#xD;
             within 3 months prior to Screening, or participants who have undergone percutaneous&#xD;
             coronary intervention or a coronary artery bypass graft within 6 months prior to&#xD;
             Screening or who are due to undergo these procedures at the time of Screening.&#xD;
&#xD;
          -  Severe congestive heart failure (NYHA III or IV).&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>30 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Joel Neutel, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Orange County Research Center</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Christopher Farina, MS, RAC</last_name>
    <phone>424-263-6364</phone>
    <email>info@abcentra.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>CCT- Research at the center for Dermatology and Plastic Surgery</name>
      <address>
        <city>Scottsdale</city>
        <state>Arizona</state>
        <zip>85260</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Kenneth Steil, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Derm Institute &amp; Skin Care Ctr., Inc.</name>
      <address>
        <city>Santa Monica</city>
        <state>California</state>
        <zip>90404</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Paul Yamauchi, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Orange County Research Center</name>
      <address>
        <city>Tustin</city>
        <state>California</state>
        <zip>92780</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Joel Neutel, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Blue Coast Research Center</name>
      <address>
        <city>Vista</city>
        <state>California</state>
        <zip>92083</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <investigator>
      <last_name>Hahn Bui, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Jacksonville Center for Clinical Research</name>
      <address>
        <city>Jacksonville</city>
        <state>Florida</state>
        <zip>32216</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Jeffrey Jacqmein, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Dawes Fretzin Clinical Research Group, LLC</name>
      <address>
        <city>Indianapolis</city>
        <state>Indiana</state>
        <zip>46250</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <investigator>
      <last_name>Kenneth Dawes, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Las Vegas Clinical Trials</name>
      <address>
        <city>Las Vegas</city>
        <state>Nevada</state>
        <zip>89030</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Alton Walters, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Excel Clinical Research</name>
      <address>
        <city>Las Vegas</city>
        <state>Nevada</state>
        <zip>89109</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Duane Anderson, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Vital Prospects Clinical Research Institute, PC</name>
      <address>
        <city>Tulsa</city>
        <state>Oklahoma</state>
        <zip>85260</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Iftkha Hussain, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>SMS Clinical Research</name>
      <address>
        <city>Mesquite</city>
        <state>Texas</state>
        <zip>75149</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Salma Saiger, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Texas Dermatology and Laser Specialists</name>
      <address>
        <city>San Antonio</city>
        <state>Texas</state>
        <zip>78218</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>John Browning, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Center for Clinical Studies, LTD.LLP</name>
      <address>
        <city>Webster</city>
        <state>Texas</state>
        <zip>77598</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Patricia Lee, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>CCT Research - Springville Dermatology</name>
      <address>
        <city>Springville</city>
        <state>Utah</state>
        <zip>84663</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <investigator>
      <last_name>Michael Peterson, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>July 2021</verification_date>
  <study_first_submitted>February 16, 2021</study_first_submitted>
  <study_first_submitted_qc>February 25, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">March 2, 2021</study_first_posted>
  <last_update_submitted>July 29, 2021</last_update_submitted>
  <last_update_submitted_qc>July 29, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">August 2, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Coronary Artery Disease</mesh_term>
    <mesh_term>Psoriasis</mesh_term>
    <mesh_term>Metabolic Syndrome</mesh_term>
    <mesh_term>Inflammation</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

